DUBLIN, Ireland & CAMBRIDGE, United Kingdom & BRISBANE, Australia–(BUSINESS WIRE)–Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces that healthy volunteers have been successfully dosed in the company’s Phase I clinical trials of Inzomelid and Somalix, two small molecule inhibitors of the NLRP3 inflammasome. These trials represent an important milestone for Inflazome and confirm its leadership in the inflammasome space. Activation of the NLRP3 inflammasome in the body drives harmful inflammation, and is implicated in many diseases. Inzomelid and Somalix are two potent and molecules designed to inhibit activation of NLRP3 and reduce

This content is restricted to site members. If you are an existing user, please log in. New users may register too.